Cover Image

PAPERBACK
$54.00



View/Hide Left Panel

Tatiana Gremyakova is chief science coordinator of biotechnology at the International Science and Technology Center (ISTC) in Moscow. She graduated from the Medical-Biological Faculty of Moscow Medical Institute (1979) and received her Ph.D. degree at the Moscow Mechnikov Institute of Vaccine and Sera (1983). She joined the State Research Center for Applied Microbiology in Obolensk, and received her doctor of medical sciences degree in 2004. Her areas of interest are microbiology, biochemistry, diagnostics, drug and vaccine development, biosafety, and biosecurity. She is the author of nearly 70 Russian and international scientific publications. She has served as chair of the ISTC’s BioCom, where she developed and managed projects with governmental and business partners. She has participated in developing more than 150 international projects (R&D and science infrastructure) in medicine, pharmacology, agriculture, industrial biotech, biosafety, and physical security in Russia, Armenia, Belarus, Georgia, and Kazakhstan. Currently, she serves as an expert at the Analytical Center of the Russian Government, where she supports projects of interest to the President’s Commission on Modernization and Technological Development. She is a member of the International Society of Infectious Diseases.

Oleg Kiselev is a member of the Russian Academy of Medical Sciences. He is director of the Research Institute of Influenza in St. Petersburg. Currently a professor of molecular virology, he graduated from the internal medicine faculty of the I.P. Pavlov First Medical Institute. In 1972, he received his Ph.D. degree in biochemical genetics at this Institute in mitochondrial biogenesis, and in 1979, he received a doctor of science degree in molecular biology. Later, he moved to the Ministry of Microbiological Industry as head of the Division of Genetic Engineering for development and manufacture of recombinant interferon. He received patents for IL-2 and IFN-alpha producer strains and technology for their production. Beginning in 1988, he has served as director of the Research Institute of Influenza. The institute has become the national World Health Organization (WHO) Center for Influenza Control and Surveillance. The institute includes a Clinical Department headed by Professor Kiselev, where every year new influenza vaccines are tested and approved according to WHO recommendations. He has been the project leader on a number of international grants: DelNS–vaccine development and production (Green Hills Biotechnology); Antiinfluenza siRNA (SirnaOmics); new antiviral drugs and production technology—Triazavirin—with wide spectra of antiviral activity; and others in the field of influenza. He has published 12 books in the fields of influenza, prions, herpes virus infection treatment, papilloma virus pathogenesis, and cancer development.

James LeDuc is director of the Galveston National Laboratory (GNL) located on the campus of the University of Texas Medical Branch in Galveston, Texas. He is also a professor in the Department of Microbiology and Immunology and holds the Robert E. Shope and John S. Dunn Distinguished Chair in Global Health. He



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement